22 November, 2022

Byotrol plc

("Byotrol" or the "Company")

Directorate Changes

Byotrol plc, the developer of anti-microbial hygiene technologies, announces the following long-planned board changes.

·    John Langlands, Non-Executive Chairman since February 2017, has notified the Board of his wish to retire from business and to step-down as Chairman and as a Director of Byotrol.  John originally only intended to serve as Chairman of Byotrol for five years, but has remained slightly longer to guide the Company through this year's AGM. John will initially remain as a Non Executive Director to aid the leadership transition, but will then retire as a Director on 31 January 2023, having completed 6 years of service.

·    David Traynor, Chief Executive Officer since October 2013 is moving to Executive Chairman, with immediate effect. In addition to his responsibilities as Chairman, David will now focus on securing and developing intellectual property agreements and commercial alliances for the Company.

·    Vivan Pinto, currently Byotrol's Chief Growth Officer, and formerly VP and Area MD at Johnson and Johnson Consumer Health, is being promoted to Chief Executive Officer and joins the Board as an Executive Director with immediate effect. He will now assume formal responsibility for the day-to-day sales and operations of the Company, working closely with Chris Sedwell, Executive Director and Chief Financial Officer.

The Board wishes to express formally its sincere thanks to John Langlands for his guidance and advice to the Company over the last six years, during highly volatile market conditions.

John Langlands, outgoing Non-Executive Chairman, commented:

"I have certainly enjoyed my time as Chairman of Byotrol, but with the pandemic now subsiding and the Byotrol team and its technologies so much improved, it is the right time for me to step-down. I will remain a supportive shareholder and will continue to offer the team advice where I can." 

David Traynor, incoming Executive Chairman, commented:

"We are very grateful to John for his excellent contribution to the Company through some extraordinary times and wish him every happiness in his retirement. We will certainly miss his calm, pragmatic and good-humoured presence in the Company.

"I am looking forward to taking over as Chairman of the Company and handing the CEO reins across to Vivan Pinto. Vivan has had a big impact on our business so far and has an excellent track record of building healthy businesses at all operational levels."

Vivan Pinto, incoming Chief Executive Officer, commented:

"Byotrol has built an exceptional base of technology platforms, the most recent of which we launched last week at the London Vet Show.  I know we can bring those technologies to more customers in more geographies and I am looking forward to making it happen."

AIM Rules, Schedule 2(g) disclosures:

In accordance with Schedule 2(g) of the AIM Rules, Vivan Francis Pinto, aged 49, holds or has held, within the last five years, the following directorships and partnerships:

At the date of this announcement, Mr Pinto has an interest in 300,000 ordinary shares representing 0.07% of the total voting rights of the Company and 3,076,923 Convertible Loan Notes, which if fully converted would represent an additional 0.68% of the total voting rights of the Company.

There is no further information disclosable in respect of Vivan Pinto pursuant to Schedule 2(g) of the AIM rules for companies.